SGP
SpyGlass Pharma, Inc. Common Stock NASDAQ$23.98
Mkt Cap $801.6M
52w Low $20.15
31.2% of range
52w High $32.44
50d MA $25.43
200d MA $25.66
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
—
ROE
—
P/FCF
—
RSI (14)
—
ATR (14)
—
Beta
0.00
50d MA
$25.43
200d MA
$25.66
Avg Volume
129.5K
About
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.57 | -5.72 | -896.1% | 25.20 | -2.3% | -10.3% | -7.3% | +2.8% | -3.0% | -10.9% | -6.2% | — |
Recent Filings
8-K
Tyra Biosciences, Inc. -- 8-K Filing
Tyra Biosciences appointed a board member with significant biopharmaceutical experience, including prior roles at Blueprint Medicines (acquired by Sanofi) and other therapeutic companies.
Apr 17
8-K
Unknown — 8-K Filing
Blco's phase 1/2 data showing 97% of patients eliminated eye drop dependency suggests strong commercial potential for its implantable device, making the $172.5M IPO attractive for investors seeking ophthalmology innovation exposure.
Mar 26
8-K · 8.01
!! High
SpyGlass Pharma, Inc. -- 8-K 8.01: Material Event / Announcement
SpyGlass Pharma reported positive 12-month clinical data from its Bimatoprost Drug Pad-IOL System Phase 1/2 trial, supporting continued development of this innovative intraocular lens technology for treating glaucoma.
Mar 9
8-K · 5.02
!!! Very High
SpyGlass Pharma, Inc. -- 8-K 5.02: Executive Change
SpyGlass Pharma appointed an executive officer to its board of directors, potentially signaling leadership transition and expanded governance responsibilities for the company.
Feb 13
8-K · 7.01
! Medium
SpyGlass Pharma, Inc. -- 8-K 7.01: Regulation FD Disclosure
SpyGlass Pharma disclosed information channels for material announcements, signaling it will communicate updates through SEC filings, its website, press releases, and public calls.
Feb 9
Data updated apr 27, 2026 1:01am
· Source: massive.com